Endra Life Sciences Inc. NDRA
We take great care to ensure that the data presented and summarized in this overview for ENDRA Life Sciences Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in NDRA
Top Purchases
Top Sells
About NDRA
ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
Insider Transactions at NDRA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 18
2023
|
Michael Milos Thornton Chief Technology Officer |
BUY
Open market or private purchase
|
Direct |
15,000
+30.53%
|
$15,000
$1.65 P/Share
|
|
May 02
2023
|
Anthony Digiandomenico Director |
BUY
Open market or private purchase
|
Direct |
83,333
+44.86%
|
$83,333
$1.2 P/Share
|
|
Dec 09
2022
|
Michael Milos Thornton Chief Technology Officer |
BUY
Open market or private purchase
|
Direct |
1,500
+7.27%
|
$4,500
$3.4 P/Share
|
|
Nov 23
2022
|
Alexander Y Tokman Director |
BUY
Open market or private purchase
|
Direct |
10,000
+5.79%
|
$0
$0.17 P/Share
|
|
Aug 22
2022
|
Michael Milos Thornton Chief Technology Officer |
BUY
Open market or private purchase
|
Direct |
20,000
+5.37%
|
$0
$0.27 P/Share
|
|
Aug 22
2022
|
Alexander Y Tokman Director |
BUY
Open market or private purchase
|
Direct |
20,000
+11.57%
|
$0
$0.26 P/Share
|
|
May 26
2022
|
Michael Milos Thornton Chief Technology Officer |
BUY
Open market or private purchase
|
Direct |
25,000
+6.99%
|
$0
$0.21 P/Share
|
|
May 18
2022
|
Michael Milos Thornton Chief Technology Officer |
BUY
Open market or private purchase
|
Direct |
25,000
+7.51%
|
$0
$0.22 P/Share
|
|
May 17
2022
|
Francois Roger Michelon Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,100
+4.99%
|
$0
$0.19 P/Share
|
|
May 16
2022
|
Alexander Y Tokman Director |
BUY
Open market or private purchase
|
Direct |
100,000
+42.94%
|
$0
$0.2 P/Share
|
|
Aug 26
2021
|
Lou Basenese Director |
SELL
Open market or private sale
|
Direct |
5,000
-9.25%
|
$5,000
$1.85 P/Share
|
|
Aug 25
2021
|
Lou Basenese Director |
SELL
Open market or private sale
|
Direct |
45,000
-45.42%
|
$45,000
$1.83 P/Share
|
|
Apr 07
2021
|
Michael Milos Thornton Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
15,000
-5.46%
|
$30,000
$2.53 P/Share
|
|
Mar 29
2021
|
Michael Milos Thornton Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
18,750
-6.38%
|
$37,500
$2.37 P/Share
|
|
Feb 11
2021
|
Michael Milos Thornton Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,815
+6.72%
|
-
|
|
Jan 28
2021
|
Michael Milos Thornton Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,815
+6.72%
|
-
|
|
Jan 13
2021
|
Renaud Bertrand Maloberti Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
13,696
-89.66%
|
$13,696
$1.1 P/Share
|
|
Jan 12
2021
|
Renaud Bertrand Maloberti Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
6,304
-29.21%
|
$6,304
$1.05 P/Share
|
|
Jan 08
2021
|
Alexander Y Tokman Director |
SELL
Open market or private sale
|
Direct |
10,000
-23.33%
|
$0
$0.9 P/Share
|
|
Jan 08
2021
|
Renaud Bertrand Maloberti Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
8,731
-28.8%
|
$0
$0.94 P/Share
|